Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 trial of TLN-372 alone and with other anti-tumor agents in advanced KRAS mutant solid tumors
2025-523086-22-00Phase 2Authorised
- Sponsor
- Treeline Biosciences
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of TLN-372 in Nonhematologic neoplasms (4 arms), sponsored by Treeline Biosciences. Primary endpoints: Number of patients experiencing dose-limiting toxicities (DLTs), Incidence and severity of TEAEs and TRAEs leading to dose modification and discontinuation and 1 more. Planned start Jan 2026; status: authorised.
02
Drugs
TLN-372
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-523086-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523086-22-00.